Human fibrinogen concentrate - CSL Behring

Drug Profile

Human fibrinogen concentrate - CSL Behring

Alternative Names: Fibrinogen Concentrate (Human); Haemocomplettan P; RiaSTAP

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; Rigshospitalet
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Afibrinogenaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Afibrinogenaemia
  • Phase III Surgical blood loss
  • Phase II Haemorrhage

Most Recent Events

  • 20 Apr 2017 CSL Behring completes a clinical trial in Haemorrhage (Adjunctive treatment) in United Kingdom (IV) (UKCRN19181)
  • 02 Mar 2016 CSL Behring completes the FIBCON trial in Surgical blood loss (In infants, In neonates) in United Kingdom (EudraCT2013-003532-68)
  • 10 Jun 2015 Phase III development for Surgical blood loss is ongoing in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top